Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in CRISPR Therapeutics AG or Beam Therapeutics Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how CRISPR Therapeutics AG and Beam Therapeutics Inc. compare based on key financial metrics to determine which better meets your investment needs.

About CRISPR Therapeutics AG and Beam Therapeutics Inc.

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company’s CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company’s lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient’s hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Latest Biotechnology and CRISPR Therapeutics AG, Beam Therapeutics Inc. Stock News

As of April 23, 2026, CRISPR Therapeutics AG had a $5.3 billion market capitalization, compared to the Biotechnology median of $280.1 million. CRISPR Therapeutics AG’s stock is up 3.3% in 2026, down 6.6% in the previous five trading days and up 40.66% in the past year.

Currently, CRISPR Therapeutics AG does not have a price-earnings ratio. CRISPR Therapeutics AG’s trailing 12-month revenue is $3.5 million with a % net profit margin. Year-over-year quarterly sales growth most recently was -97.5%. Analysts expect adjusted earnings to reach $-4.940 per share for the current fiscal year. CRISPR Therapeutics AG does not currently pay a dividend.

As of April 23, 2026, Beam Therapeutics Inc. had a $3.0 billion market cap, putting it in the 60th percentile of all stocks. Beam Therapeutics Inc.’s stock is up 10% in 2026, down 2.9% in the previous five trading days and up 57.66% in the past year.

Currently, Beam Therapeutics Inc. does not have a price-earnings ratio. Beam Therapeutics Inc.’s trailing 12-month revenue is $139.7 million with a -57.2% net profit margin. Year-over-year quarterly sales growth most recently was 279.1%. Analysts expect adjusted earnings to reach $-4.314 per share for the current fiscal year. Beam Therapeutics Inc. does not currently pay a dividend.

How We Compare CRISPR Therapeutics AG and Beam Therapeutics Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at CRISPR Therapeutics AG and Beam Therapeutics Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

CRISPR Therapeutics AG and Beam Therapeutics Inc. Stock Value Grades

Company	Ticker	Value
CRISPR Therapeutics AG	CRSP	na
Beam Therapeutics Inc.	BEAM	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

CRISPR Therapeutics AG does not have a meaningful Value Score. Beam Therapeutics Inc. has a Value Score of 9, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither CRISPR Therapeutics AG or Beam Therapeutics Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if CRISPR Therapeutics AG or Beam Therapeutics Inc. is the better investment when it comes to value.

CRISPR Therapeutics AG and Beam Therapeutics Inc.’s Quality Grades

Company	Ticker	Quality
CRISPR Therapeutics AG	CRSP	D
Beam Therapeutics Inc.	BEAM	D

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

CRISPR Therapeutics AG has a Quality Score of 28, which is Weak. Beam Therapeutics Inc. has a Quality Score of 25, which is Weak.

The Quality Stock Winner: No Clear Winner

Neither CRISPR Therapeutics AG or Beam Therapeutics Inc. has a high enough Quality Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if CRISPR Therapeutics AG or Beam Therapeutics Inc. is the better investment when it comes to quality.

CRISPR Therapeutics AG and Beam Therapeutics Inc.’s Momentum Grades

Company	Ticker	Momentum
CRISPR Therapeutics AG	CRSP	B
Beam Therapeutics Inc.	BEAM	B

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

CRISPR Therapeutics AG has a Momentum Score of 66, which is Strong. Beam Therapeutics Inc. has a Momentum Score of 64, which is Strong.

The Momentum Grade Winner: It’s a Tie!

Looking at the Momentum Grade breakdown above, both CRISPR Therapeutics AG and Beam Therapeutics Inc. have a grade of B. For those who focus solely on a company’s momentum, further research will need to be conducted into both companies to see if they fit your individual needs as an investor.

Other CRISPR Therapeutics AG and Beam Therapeutics Inc. Grades

In addition to Quality, Value and Momentum, A+ Investor also provides grades for Growth and Estimate Revisions.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether CRISPR Therapeutics AG and Beam Therapeutics Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, CRISPR Therapeutics AG or Beam Therapeutics Inc. Stock?

Overall, CRISPR Therapeutics AG stock has a Value Score of , Momentum Score of 66 and Quality Score of 28.

Beam Therapeutics Inc. stock has a Value Score of 9, Momentum Score of 64 and Quality Score of 25.

Comparing CRISPR Therapeutics AG and Beam Therapeutics Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.